MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, WVE had -$12,251K decrease in cash & cash equivalents over the period. -$44,914K in free cash flow.

Cash Flow Overview

Change in Cash
-$12,251K
Free Cash flow
-$44,914K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-53,852 -97,347
Amortization of right-of-use assets
1,374 2,620
Depreciation of property and equipment
856 1,740
Share-based compensation expense
6,472 11,149
Accounts receivable
8,383 195
Prepaid expenses
-47 -2,844
Other assets
-4,847 81
Accounts payable
59 -1,776
Accrued expenses and other current liabilities
3,461 -8,055
Deferred revenue
2,392 -16,257
Operating lease liabilities
-1,939 -3,693
Net cash used in operating activities
-44,666 -109,051
Purchases of property and equipment
248 471
Net cash used in investing activities
-248 -471
Proceeds from the issuance of ordinary shares, net of offering costs
0 -
Proceeds from the issuance of pre-funded warrants, net of offering costs
0 -
Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs
30,212 12,361
Proceeds from the exercise of share options
2,041 3,045
Proceeds from the espp
439 442
Net cash provided by financing activities
32,692 15,848
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash
-29 101
Net (decrease) increase in cash, cash equivalents, and restricted cash
-12,251 -93,573
Cash and cash equivalents at beginning of period
305,838 -
Cash and cash equivalents at end of period
200,014 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Wave Life Sciences Ltd. (WVE)

Wave Life Sciences Ltd. (WVE)